Back to Search Start Over

Enhancing Methotrexate Delivery in the Brain by Mesoporous Silica Nanoparticles Functionalized with Cell-Penetrating Peptide using in Vivo and ex Vivo Monitoring.

Authors :
Shadmani N
Makvandi P
Parsa M
Azadi A
Nedaei K
Mozafari N
Poursina N
Mattoli V
Tay FR
Maleki A
Hamidi M
Source :
Molecular pharmaceutics [Mol Pharm] 2023 Mar 06; Vol. 20 (3), pp. 1531-1548. Date of Electronic Publication: 2023 Feb 10.
Publication Year :
2023

Abstract

The blood-brain barrier (BBB) acts as a physical/biochemical barrier that protects brain parenchyma from potential hazards exerted by different xenobiotics found in the systemic circulation. This barrier is created by "a lipophilic gate" as well as a series of highly organized influx/efflux mechanisms. The BBB bottleneck adversely affects the efficacy of chemotherapeutic agents in treating different CNS malignancies such as glioblastoma, an aggressive type of cancer affecting the brain. In the present study, mesoporous silica nanoparticles (MSNs) were conjugated with the transactivator of transcription (TAT) peptide, a cell-penetrating peptide, to produce MSN-NH-TAT with the aim of improving methotrexate (MTX) penetration into the brain. The TAT-modified nanosystem was characterized by Fourier transform infrared spectrometry (FTIR), field emission scanning electron microscopy (FE-SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM), dynamic light scattering (DLS), and N <subscript>2</subscript> adsorption-desorption analysis. In vitro hemolysis and cell viability studies confirmed the biocompatibility of the MSN-based nanocarriers. In addition, in vivo studies showed that the MTX-loaded MSN-NH-TAT improved brain-to-plasma concentration ratio, brain uptake clearance, and the drug's blood terminal half-life, compared with the use of free MTX. Taken together, the results of the present study indicate that MSN functionalization with TAT is crucial for delivery of MTX into the brain. The present nanosystem represents a promising alternative drug carrier to deliver MTX into the brain via overcoming the BBB.

Details

Language :
English
ISSN :
1543-8392
Volume :
20
Issue :
3
Database :
MEDLINE
Journal :
Molecular pharmaceutics
Publication Type :
Academic Journal
Accession number :
36763486
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.2c00755